The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

This study presents a phase-field crystal model that simulates AB-BA transitions in bilayer graphene, highlighting defect ...

Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

FormFactor (FORM) shares declined nearly 5% after Texas Instruments issued a cautious outlook and a slight profit miss, which dampened sentiment throughout the semiconductor sector. The move ...

England qualified for the 2026 World Cup with two games to spare England secured their place at the 2026 World Cup with a comfortable victory against Latvia on Tuesday night. BBC Sport's Senior ...

Arne Slot has played down Mohamed Salah’s slow start to season but admitted Liverpool’s adjustment to life without Trent Alexander-Arnold could be a factor. Salah, 33, was dropped for a second ...

Shares of semiconductor testing company FormFactor (NASDAQ:FORM) jumped 6.3% in the afternoon session after B. Riley upgraded its rating on the stock from Neutral to Buy and significantly raised its ...